Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer

Trial Status: active

This phase II trial studies the effect of mirvetuximab soravtansine in treating patients with folate receptor-alpha positive endometrial cancer that remains despite treatment (persistent) or has come back (recurrent). Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug, called soravtansine. Mirvetuximab is a form of targeted therapy because it attaches to specific receptors on the surface of cancer cells, known as folate receptor-alpha receptors, and delivers soravtansine to kill them.